Navigation Links
Results of the ADVISE trial reported at TCT 2011
Date:11/11/2011

SAN FRANCISCO, CA NOVEMBER 11, 2011 Researchers conducting the ADVISE clinical trial have concluded that a new measure of stenosis severity, instantaneous wave-free ratio (iFR), yielded similar results to traditional fractional flow reserve (FFR) without the use of adenosine to induce maximum hyperemia. Trial results were presented today at the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation.

FFR, while the leading invasive measure of stenosis severity, is only used in 6% or fewer of percutaneous coronary intervention (PCI) cases in the United States. One of the reasons for the low usage rate is the required use of the drug adenosine, which minimizes and stabilizes coronary resistance during the test, but is uncomfortable for patients, as well as being time-consuming and expensive.

In ADVISE (ADenosine Vasodilation Independent Stenosis Evaluation), 157 stenoses (131 patients) were recruited to this pilot, nonrandomized, international, multi-center study. In their investigations, researchers developed a new pressure-based index that does not require adenosine.

Wave intensity analysis identified a period during the normal heart rhythm cycle where intracoronary resistance at rest is similar in variability and magnitude (CV: 0.080.06 and 284147mmHg.s/m) to those during FFR (CV: 0.080.06 and 302315mmHg.s/m, p=NS for both).

The resting ratio of the distal-to-proximal pressure during this period, iFR, correlated closely with FFR (r=0.9, p<0.001) with excellent diagnostic efficiency (receiver operating characteristic area under curve of 93%, at FFR<0.8), specificity, sensitivity, and negative and positive predictive values of 91%, 85%, 85% and 91%, respectively.

"The results of the ADVISE trial indicate that intra-coronary resistance is naturally constant and minimized during the wave-free period. The instantaneous wave-Free Ratio (iFR) calculated over this period produces a drug-free index of stenosis severity that is comparable to FFR," said principal investigator Justin Davies, MBBS, MRCP, PhD. Dr Davies is a clinical academic and interventional cardiologist at the National Heart and Lung Institute at Imperial College London.

"The clinical implications of the trial are that significant barriers to a physiological assessment of stenoses have been removed, and the new technique can potentially improve work-flow in the cath lab, leading to a better patient experience and increased adoption," said Dr. Davies.


'/>"/>

Contact: Judy Romero
jromero@crf.org
Cardiovascular Research Foundation
Source:Eurekalert

Related medicine news :

1. Lincare Holdings Inc. Announces Fourth Quarter and Year Ended 2009 Financial Results
2. SXC Health Solutions to Host Fiscal 2009 Fourth Quarter and Year End Results Conference Call
3. Team Health Holdings, Inc., Announces Fourth Quarter and Fiscal 2009 Financial Results
4. First blinded study of venous insufficiency prevalence in MS shows promising results
5. NEJM Publishes Trial Results Demonstrating Bard FLAIR Endovascular Stent Graft Is Superior To Balloon Angioplasty For Failing Dialysis Grafts
6. BioMed Realty Trust Reports Fourth Quarter and Full-Year 2009 Financial Results
7. Kaiser Foundation Health Plan and Hospitals Report Fourth Quarter and Fiscal Year 2009 Financial Results
8. United American Healthcare Corporation Announces Fiscal 2010 Second Quarter Results
9. Fitness Trend Towards Online Personal Training Gets Real-World Weight Loss Results on FitOrbit.com
10. Protein Sciences Corporation Announces Profitable and Cash Flow Positive Results for 2009 and Management Realignment
11. WebMD Announces Fourth Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... D.C. (PRWEB) , ... February 11, 2016 , ... ... will be exhibiting at the American Academy of Dermatology Annual Meeting at the ... USA's goal is to raise awareness for both the condition of hyperhidrosis (excessive ...
(Date:2/11/2016)... CA (PRWEB) , ... February 11, 2016 , ... ... was held in San Diego, CA, on February 6th & 7th, 2016 according to ... for those who were not invited to the NFL’s combine in Indianapolis,” says Husted. ...
(Date:2/11/2016)... ... ... The book, “Computers Should Just Work!”, provides a basic, non-techie education on ... before signing a contract and how to spot an incompetent or dishonest IT person ... e-mail and technology, it’s more important than ever to make sure the company you ...
(Date:2/11/2016)... ... , ... As part of their 2015 end of year funding strategy, ... has gifted $10,000 to University of Chicago to support ovarian cancer research being conducted ... are honored to support a promising young investigator from Dr. Lengyel’s lab at the ...
(Date:2/10/2016)... ... February 10, 2016 , ... The 9th annual ... Imaging Congress (WMIC), will be held in New York City, NY on September ... Therapy.” The congress will highlight and emphasize how imaging reveals a greater understanding ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... NEW YORK , Feb. 11, 2016 /PRNewswire/ ... a foot-focused suite of products designed to support ... ExoSOLS™, are custom orthotic insoles that combine years ... 1,000 partners in the podiatric field with cutting ... align, and propel . It is supported by ...
(Date:2/11/2016)... , February 11, 2016 ... Market Report 2016 research report provides information on ... development status with crucial statistical data and information ... http://www.deepresearchreports.com/142870.html . --> Complete report on ... companies and supported with 296 tables and figures ...
(Date:2/10/2016)... 2016   Genomic Health, Inc. (Nasdaq: GHDX ) ... year ended December 31, 2015. --> ... 2015, compared with $69.1 million in the fourth quarter of 2014, ... increased 9 percent compared with the same period in the prior ... was $63.9 million in the fourth quarter of 2015, an increase ...
Breaking Medicine Technology: